[Botulinum toxin in nonneurogenic bladder dysfunction].
Nonneurogenic overactive bladder with or without detrusor overactivity and/or incontinence is a bothersome symptom for many people. Until a few years ago, it could be treated only with anticholinergic drugs or invasive surgery. Intradetrusor injection with botulinum toxin type A is a minimally invasive alternative therapy option for patients who do not respond to or tolerate anticholinergic treatment. This literature overview summarises the relevant articles on this topic over the last 6 years and provides information on the efficacy, adverse events, currently used dosages, and injection techniques. Overall, a favourable initial efficacy has been observed starting around day 4 after injection and can last up to approximately 31 weeks. Depending on the dose, however, elevated postvoid residual volumes should be anticipated and might require clean intermittent self-catheterisation. The use of botulinum toxin in the urinary bladder is still considered off-label.
Mehnert
U
U
Neurourologie, Spinal Cord Injury Center, Uniklinik Balgrist, Zürich, Schweiz.
Schurch
B
B
D001905:Botulinum Toxins / Q000008:administration & dosage* / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D001750:Urinary Bladder, Neurogenic; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000517:prevention & control*
D001905:Botulinum Toxins